News

LNC Therapeutics acquires exclusive license for the Christensenella patent from Cornell University

Oct 15, 2018

LNC Therapeutics launches a new clinical trial, OBEMINALE 2, and treats its first patient

Oct 2, 2018

Christensenella: the cornerstone of the gut microbiota?

Jul 6, 2018

LNC Therapeutics appoints new CEO, Dr. Georges Rawadi, and accelerates development in microbiome...

Apr 17, 2018

LNC Therapeutics raises € 6,5 million and reinforces its R&D in the Microbiota field

Sep 27, 2017